Analysis of the side effects and effects of ensidipine

Enasidenib (Enasidenib) is a targeted therapy for patients with acute myeloid leukemia (AML) carrying IDH2 gene mutations.

Digestive system reactions: such as nausea, vomiting, diarrhea and loss of appetite. These reactions are usually noticeable early in treatment, but their incidence and severity may gradually decrease as treatment continues. Digestive system reactions may affect patients' nutritional intake and quality of daily life.

Systemic symptoms: such as fatigue, joint pain, and rash. These symptoms may have some impact on the patient's daily life, but are usually not life-threatening.

Blood system reactions: such as anemia, thrombocytopenia, and neutropenia. These reactions may cause patients to experience symptoms such as bleeding and infection, which may be life-threatening in severe cases. Therefore, it is necessary to closely monitor the patient's blood routine indicators and take corresponding treatment measures in a timely manner.

Abnormal liver function: If serum bilirubin is elevated, symptoms such as jaundice, yellowish skin staining, and dark urine may occur. Abnormal liver function may affect drug metabolism and excretion, increasing the risk of adverse reactions. Therefore, patients’ liver function indicators need to be monitored regularly and the medication regimen adjusted as needed.

Electrolyte disorders: such as hyperkalemia and hyperuricemia. These reactions may cause patients to experience symptoms such as muscle weakness, cardiac arrhythmias, joint pain, and urinary tract stones. Electrolyte imbalances may affect multiple organ systems in patients and require prompt correction.

Ensidipine may weaken the patient's immunity and increase the risk of infection. Infections such as bacteria, fungi, and viruses, in particular, may cause serious complications such as sepsis, sepsis, and shock.

Because ensidipine may cause hematologic reactions such as thrombocytopenia, patients may be at increased risk of bleeding. Severe bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, and urinary tract bleeding can be life-threatening.

Individual patients may have electrocardiogram abnormalities, such as QT interval prolongation, which increases the risk of arrhythmia. Arrhythmias can lead to serious complications such as cardiac arrest, cardiogenic shock, and myocardial infarction.

During the period of using ensidipine, patients should receive regular examinations from their doctors, closely monitor relevant indicators, and promptly report any symptoms of discomfort. If serious side effects or allergic reactions occur, inform your doctor immediately and stop using ensidipine. The doctor will adjust the medication plan or take other treatment measures according to the patient's specific situation.

References:

https://my.clevelandclinic.org/health/drugs/20910-enasidenib-tablets